Discovery of a novel and potent class of fabI-directed antibacterial agents

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 10, 2002, Pages 3118-3124

  Payne, David J ^a   Miller, William H ^a   Berry, Valerie ^a   Brosky, John ^a   Burgess, Walter J ^a   Chen, Emile ^a   DeWolf Jr , Walter E ^a   Fosberry, Andrew P ^a   Greenwood, Rebecca ^a   Head, Martha S ^a   Heerding, Dirk A ^a   Janson, Cheryl A ^a   Jaworski, Deborah D ^a   Keller, Paul M ^a   Manley, Peter J ^a   Moore, Terrance D ^a   Newlander, Kenneth A ^a   Pearson, Stewart ^a   Polizzi, Brian J ^a   Qiu, Xiayang ^a   Rittenhouse, Stephen F ^a   Slater Radosti, Courtney ^a   Salvers, Kevin L ^a   Seefeld, Mark A ^a   Smyth, Martin G ^a   Takata, Dennis T ^a   Uzinskas, Irene N ^a   Vaidya, Kalindi ^a   Wallis, Nicola G ^a   Winram, Scott B ^a   Yuan, Catherine C K ^a   Huffman, William F ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL CARRIER PROTEIN REDUCTASE; AMOXICILLIN; ANTIINFECTIVE AGENT; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; FATTY ACID; GENTAMICIN; MEROPENEM; N METHYL N (2 METHYL 1H INDOL 3 YLMETHYL) 3 (7 OXO 5,6,7,8 TETRAHYDRO 1,8 NAPHTHYRIDIN 3 YL)ACRYLAMIDE; OXACILLIN; OXIDOREDUCTASE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CATALYSIS; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; ENTEROCOCCUS FAECALIS; ENZYME INHIBITION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; OXIDOREDUCTASES; RATS; RATS, SPRAGUE-DAWLEY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036783668     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.10.3118-3124.2002     Document Type: Article

References (17)

1. A mechanism of drug action revealed by structural studies of enoyl reductase
2. The millennium bugs - The need for and development of new antibacterials
3. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA
4. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis
5. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli
6. A triclosan-resistant bacterial enzyme
7. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): A target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis
8. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy
9. Triclosan targets lipid synthesis
10. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)
11. Bacterial fatty acid biosynthesis: A genomics driven target for antibacterial drug discovery
12. The acrAB homolog of Haemophilus influenzae codes for a functional efflux pump
13. Current approaches to overcome bacterial resistance
14. Biochemical and genetic characterisation of the action of triclosan on Staphylococcus aureus
15. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae